Page Title
Clinical Trial Finder
You can help advance cystic fibrosis research — starting now.
Tailor your search using the filters on the left.
Need help? Watch a video tutorial or contact the Clinical Trial Navigator, a real person who can assist you.
Showing 1-1 of 1 studies
Tailor your search using the filters on the left.
Need help? Watch a video tutorial or contact the Clinical Trial Navigator, a real person who can assist you.
Showing 1-1 of 1 studies
-
Anti-InfectiveCompleted with Results
Study to evaluate inhaled AP-PA02 in adults with cystic fibrosis and chronic Pseudomonas aeruginosa (Armata Phase 1b/2) , protocol number Armata AP-PA02-101This study looked at the safety and tolerability of inhaled AP-PA02, a bacteriophage drug intended to treat infections in the lung. Bacteriophages are specialized viruses that kill specific bacterial strains. Multiple doses of the drug were tested in adults with cystic fibrosis and chronic Pseudomonas aeruginosa to find the best dose.
-
Age:
18 Years and Older
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
40% or greater
-
Number of Visits:
8
-
Length of Participation:
38 days
-
Showing 1-1 of 1 studies
- 1
Studies in this tool are multi-center studies facilitated by the Cystic Fibrosis Therapeutics Development Network. For a complete list of cystic fibrosis related studies, visit www.clinicaltrials.gov.
Related Topics
CONTACT THE CLINICAL TRIAL NAVIGATOR
Get personalized assistance and answers to your clinical trial questions.
Learn MoreSign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Check the Drug Development Pipeline
We’re attacking CF from every angle. Learn about the status of CF drugs in development.
Learn More